Amicus Therapeutics, Inc. $FOLD Shares Acquired by Wrapmanager Inc.

Wrapmanager Inc. boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 41.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,165 shares of the biopharmaceutical company’s stock after purchasing an additional 6,475 shares during the quarter. Wrapmanager Inc.’s holdings in Amicus Therapeutics were worth $127,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in FOLD. Wellington Management Group LLP grew its stake in shares of Amicus Therapeutics by 2.6% during the 1st quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company’s stock valued at $238,277,000 after buying an additional 738,623 shares during the period. Redmile Group LLC boosted its holdings in Amicus Therapeutics by 35.1% in the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock valued at $77,795,000 after acquiring an additional 2,478,779 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Amicus Therapeutics by 27.6% in the 1st quarter. Vestal Point Capital LP now owns 4,275,000 shares of the biopharmaceutical company’s stock worth $34,884,000 after purchasing an additional 925,000 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Amicus Therapeutics by 641.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock worth $20,249,000 after purchasing an additional 3,057,072 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Amicus Therapeutics in the 1st quarter valued at about $28,741,000.

Amicus Therapeutics Stock Up 1.1%

Shares of NASDAQ FOLD opened at $9.48 on Friday. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $10.35. The stock’s 50-day simple moving average is $8.45 and its 200-day simple moving average is $7.16. The firm has a market cap of $2.92 billion, a price-to-earnings ratio of -78.99 and a beta of 0.66.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.Amicus Therapeutics’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider David Michael Clark sold 25,643 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total value of $243,864.93. Following the completion of the sale, the insider owned 322,618 shares of the company’s stock, valued at approximately $3,068,097.18. The trade was a 7.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

FOLD has been the subject of a number of research analyst reports. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Thursday. JPMorgan Chase & Co. increased their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. The Goldman Sachs Group raised their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.